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Heterogeneous Characteristics of Korean Patients with 
Dysferlinopathy
Dysferlinopathy is caused by mutations in the DYSF gene. To characterize the clinical 
spectrum, we investigated the characteristics of 31 Korean dysferlinopathy patients 
confirmed by immunohistochemistry. The mean age of symptom onset was 22.23 ± 7.34 
yr. The serum creatine kinase (CK) was highly increased (4- to 101-fold above normal). The 
pathological findings of muscle specimens showed nonspecific dystrophic features and 
frequent inflammatory cell infiltration. Muscle imaging studies showed fatty atrophic 
changes dominantly in the posterolateral muscles of the lower limb. The patients with 
dysferlinopathy were classified by initial muscle weakness: fifteen patients with Miyoshi 
myopathy phenotype (MM), thirteen patients with limb girdle muscular dystrophy 2B 
phenotype (LGMD2B), two patients with proximodistal phenotype, and one asymptomatic 
patient. There were no differences between LGMD2B and MM groups in terms of onset 
age, serum CK levels and pathological findings. Dysferlinopathy patients usually have 
young adult onset and high serum CK levels. However, heterogeneity of clinical 
presentations and pathologic findings upon routine staining makes it difficult to diagnose 
dysferlinopathy. These limitations make immunohistochemistry currently the most 
important method for the diagnosis of dysferlinopathy.
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INTRODUCTION
Dysferlinopathy is an autosomal recessive disease caused by a 
DYSF (MIM*603009) gene mutation, located on chromosome 
2p13 (1). Dysferlin encoded by the DYSF gene is a 230 kDa pro-
tein with seven C2 domains and a single transmembrane do-
main at the C terminus. Dysferlin is homologous to the Cae-
norhabditis elegans spermatogenesis factor fer-1 protein that 
mediates fusion of intracellular vesicles to the sperm plasma 
membrane. It was suggested that dysferlin might be a vesicle-
associated membrane protein involved in docking and fusion 
of vesicles in muscle cells (2). Therefore, dysferlin has multiple 
roles in the process of membrane repair, myoblast differentia-
tion, T tubulogenesis and muscle regeneration (3-5). Although 
dysferlinopathy is caused by a single DYSF gene, it is well-known 
that dysferlinopathy has various clinical presentations such as 
distal Miyoshi myopathy (MM), limb girdle muscular dystrophy 
2B (LGMD2B), mixed proximodistal (PD), distal anterior com-
partment myopathy (DACM) and asymptomatic groups (1, 6, 7). 
This heterogeneity was observed even in the same family with 
the same mutation (8, 9). It is well-known that LGMD2B is one 
of the most common forms of limb girdle muscular dystrophy 
(10, 11). However, there are few reports of patients with dysfer-
linopathy in Korea (12-14). To characterize the clinical spectrum 
of Korean dysferlinopathy, we investigated clinical, pathologi-
cal, laboratory, and radiological features of dysferlinopathy ex-
hibited by Korean patients. 
MATERIALS AND METHODS
Subjects
For this study, we reviewed muscle specimens referred to Gang-
nam Severance Hospital from March 2004 to June 2011. Each 
muscle specimen was obtained from the patients with suspected 
myopathy. We found 33 cases with complete or nearly complete 
dysferlin protein loss in the muscle specimens by immunohis-
tochemistry (Fig. 1A, B). Two patients were withheld due to in-
complete medical records. Finally, 31 patients were enrolled for 
this study. We studied clinical, laboratory, pathologic and radio-
logic features of each patient. Clinical data included sex, age of 
symptom onset, disease duration, initial pattern of muscle in-
volvement, family history, and distribution of weakness at diag-
nosis. Muscle involvement was evaluated clinically using medi-
cal research council scales. Laboratory findings included cre-
atine kinase (CK) levels, needle electromyography, and electro-
cardiography. The serum CK levels were expressed as ×-fold the 
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upper limit of normal values according to the local reference 
range. Radiological findings were included muscle CT or MRI 
scans. Muscle specimens were taken from the following muscles: 
the vastus lateralis (n = 12), biceps brachii (n = 9), deltoid (n =  
1), and unspecified muscles (n = 9). The frozen muscle sections 
(5 μm thickness) from all muscle specimens were stained with 
routine histopathological stains such as hematoxylin and eosin 
(H&E), modified Gomori trichrome (modified GT), and nico-
tinamide adenine dinucleotide-tetrazolium reductase (NADH-
TR) stains. 
Immunohistochemistry of muscle specimens
The tissues were processed for immunohistochemistry as fol-
lows: 5-μm transverse serial sections were obtained from all mus-
cle specimens. Sections were fixed in acetone at 4°C for 10 min, 
rinsed in 50 mM Tris-buffered saline (pH 7.5) for 20 min, and 
incubated for 30 min with a blocking solution containing 2% 
bovine serum albumin and 5% normal goat serum as described 
(15). The sections were then incubated overnight in a humid 
chamber at 4°C with one of the following antibodies: C-termi-
nal of dystrophin (Leica Microsystems, Newcastle upon Tyne, 
UK), rod domain of dystrophin (Leica Microsystems), N-termi-
nal of dystrophin (Leica Microsystems), dysferlin (Leica Micro-
systems), α-sarcoglycan (Leica Microsystems), β-sarcoglycan 
(Leica Microsystems), γ-sarcoglycan (Leica Microsystems), and 
δ-sarcoglycan (Leica Microsystems), α-dystroglycan (Millipore, 
Billerica, MA, USA), and caveolin (BD Biosciences, San Diego, 
CA, USA). After washing for 20 min in Tris-buffered saline, the 
sections were incubated with biotinylated goat anti-mouse IgG 
(Vector Laboratories Inc., Burlingame, CA, USA) for 30 min at 
room temperature followed by detection with streptavidin-bio-
tin complex immunoperoxidase (VECTASTAIN Elite ABC kit; 
Vector Laboratories Inc.). Then the slides were developed with 
3, 3´-diaminobenzidine (DAB substrate kit for peroxidase; Vec-
tor Laboratories Inc.) substrate for 1-5 min. After being washed, 
the slides were mounted in mounting medium (VectaMount; 
Vector Laboratories Inc.).
Statistical analysis
The chi-square test and the Fischer’s exact tests were used to 
compare discrete variables, and the independent t-test was used 
to compare the means of two samples for continuous variables. 
Fig. 1. Pathological features of dysferlinopathy. (A) Dysferlin in a normal muscle specimen by immunohistochemistry (× 200). (B) Loss of dysferlin in a nearly total muscle speci-
men by immunohistochemistry (× 200). (C) Prominent inflammatory cell infiltration and increased endomysial fibrosis on H&E stain (× 200). (D) A few necrotic (* ) and regener-
ating muscle fibers (■) on modified Gomori trichrome stain (× 200).
A B
C D
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The relationship between serum CK levels and age at diagnosis 
or disease duration was assessed using Pearson correlation co-
efficients. Differences were considered statistically significant 
at P < 0.05. Statistical analyses were performed with SPSS (ver-
sion 17.0). 
Ethics statement
This study protocol was approved by the institutional review board 
of Gangnam Severance hospital (IRB Number: 3-2011-0190). 
Written informed consent was exempted by the board because 
this was a retrospective study.
RESULTS
Demographic and clinical characteristics
In the study, 12 (38.9%) men and 19 (61.3%) women were in-
cluded. The mean age of symptom onset was 22.23 ± 7.34 yr 
(range, 12-36 yr), and 22 patients of 30 symptomatic patients 
(73.3%) experienced their first symptoms between 15 and 30 yr 
of age. The mean disease duration was 7.97 ± 6.94 yr (range, 1- 
30 yr). Table 1 summarizes the clinical and laboratory findings. 
Three patients had family history of myopathy. Twenty nine pa-
tients showed slowly progressive muscle weakness. However, 
one patient had become symptomatic rapidly during military 
training. One patient had only extremely high serum CK levels 
without weakness. Seven patients (23%) described very active 
and sporty life before symptom onset. Seven patients (two LG-
MD2B, four MM and one PD patients) had initially asymmetric 
muscle weakness. Muscle assessment at diagnosis revealed rel-
atively preserved muscle function in the upper limbs.
Laboratory findings
The mean serum creatine kinase (CK) level was elevated 42-fold 
(min; 4, max; 131) above the upper limit of normal values. There 
Table 1. Clinical and laboratory characteristics of 31 patients with dysferlinopathy
No.
Sex/ 
Age
(yr)
Age (yr)  
of  
onset
Clinical diagnosis before  
immunohistochemistry
F/H
Distribution of muscle weakness
EKG
Serum CK 
(fold)
U/Ex L/Ex
P D P AD PD
Group 1: LGMD2B phenotype
  1
  2
  3
  4
  5
  6
  7
  8
  9
10
11
12
13
F/15
F/43
F/45
F/18
F/36
F/37
F/30
M/31
F/51
M/20
F/34
F/40
F/37
12
36
25
12
20
32
18
15
30
14
26
35
33
LGMD
LGMD
LGMD
LGMD
LGMD
LGMD
Inflammatory myopathy
LGMD
LGMD
LGMD
LMGD
LGMD
Inflammatory myopathy
0
0
0
0
0
0
0
0
0
0
0
0
0
4+
3
5
4
4+
3
4+
4-
4-
4
5
5
3
5
4+
5
5
5
4
4+
4
4+
5
5
5
4
3
4-
4
4
4-
3
4+
4-
3+
4
4-
4+
2
4
4
5
5
4+
4+
4+
4
4
4+
4-
5
4
4
4
5
5
4+
4+
4+
4
4
4+
4-
5
4
NR
NR
WNL
NR
NR
NR
WNL
WNL
NR
NR
NR
WNL
NR
111
  13
  27
128
  17
  20
  65
  40
NR
    4
  25
  31
  10
Group 2: Miyoshi distal myopathy phenotype
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
F/38
M/25
F/26
M/21
M/20
M/22
M/33
F/23
F/33
F/36
F/33
M/50
M/22
M/30
F/26
36
23
16
16
17
21
18
16
19
30
29
20
21
29
19
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
Inflammatory myopathy
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
Inflammatory myopathy
Miyoshi myopathy
Miyoshi myopathy
Miyoshi myopathy
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
5
5
4+
5
5
5
5
4+
4+
5
5
4
5
5
5
5
5
5
5
5
5
5
4+
5
5
5
4
5
5
5
5
5
4-
5
5
4+
5
4+
4+
5
4+
4
5
4+
4+
5
5
4
4+
4+
4-
4+
4
4-
5
5
2
5
5
4+
4+
4
4
4+
4+
4
4
4-
4
4+
4+
2
4+
4
4+
NR
NR
NR
NR
NR
NR
NR
NR
WNL
WNL
NR
NR
WNL
WNL
WNL
  14
  25
  40
  48
  50
  41
  25
100
  12
  24
  33
    8
  48
  34
  30
Group3: proximodistal phenotype
29
30
F/19
M/21
17
16
LGMD
LGMD
0
0
4
5
5
5
4
4-
5
4+
4
4
NR
NR
131
  60
Group 4: asymptomatic phenotype
31 M/21 18 HyperCKemia 1 5 5 5 5 5 NR   43
U/Ex, upper extremities; L/Ex, lower extremities; P, proximal; D, distal; AD, anterior distal; PD, posterior distal; LGMD, limb girdle muscular dystrophy; NR, no record; WNL, within 
normal limit.
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was significant negative correlation between the serum CK and 
the age of patients (R = -0.652, P < 0.001). However, there was 
no significant correlation between the serum CK level and the 
disease duration (P = 0.123). Nine patients recalled that they 
had had persistent elevation of liver function tests before the on-
set of weakness and one patient (patient 29) had even received 
a liver biopsy. Needle electromyography in all patients showed 
short duration, low amplitude motor unit potentials with full 
interference patterns. Nine patients had undergone electrocar-
Table 2. Histopathological findings of muscle biopsy in 31 patients with dysferlinopathy
Findings  No. (%)
Muscle size variation
   Mild
   Moderate
   Marked
 
  7 (23)
  8 (26)
13 (42)
Small angulated fiber 0 (0)
Internal nuclei 17 (55)
Necrotic and regenerative fiber 28 (90)
Cellular response
   Inflammatory cell infiltration
   Endomysial fibrosis
 
22 (71)
20 (65)
Architectural change
   Lobulated fiber
   Rimmed vacuoles
   Target fiber
   Targetoid fiber
   Moth-eaten fiber
   Ring fiber
 
1 (3)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
Fig. 2. Radiological features of dysferlinopathy. Muscle CT scans revealed that muscles of the upper limb (A) are relatively spared and lateral posterior compartments of thigh (B) 
and calf (C) muscles had dominantly fatty atrophic changes. Transverse T1 weighted images through thigh (D) and calf (E) muscles revealed that lateral posterior muscles had 
dominantly fatty atrophic changes. 
A B C
D E
diograms and all showed normal findings. 
Pathological findings
Table 2 shows pathological findings of muscle specimens. The 
muscle specimens on routine histopathological stains (H&E, 
modified GT and NADH-TR stains) showed nonspecific dystro-
phic features of varying degrees with regard to fiber size variabil-
ity, increased endomysial fibrosis, and necrotic and regenerat-
ing muscle fibers. One muscle specimen presented lobulated 
fibers. However, routine histopathological staining of three mus-
cle specimens did not reveal any pathological changes. Inflam-
matory cells were observed in the majority of the muscle biopsies 
and were located especially in the perivascular area (Fig. 1C, D). 
In the present study, four patients had been misdiagnosed with 
inflammatory myopathy after muscle biopsy and were treated 
by steroids and immunomodulating drugs. They could have 
been properly diagnosed with immunohistochemistry for dys-
ferlin. By immunohistochemistry, all muscle specimens revealed 
normal staining pattern for other sarcolemmal proteins such as 
dystrophin, sarcoglycans, dystroglycan and caveolin. 
Radiological findings
Muscle CT scans were performed in four patients (two LGMD2B 
and two MM patients). CT scans identified the extent of replace-
ment of skeletal muscle by fat or fibrotic tissue. The upper limb 
muscles are relatively spared and the lateral posterior compart-
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http://jkms.org  427http://dx.doi.org/10.3346/jkms.2012.27.4.423
ments of the lower limb muscles had dominantly fatty atrophic 
changes (Fig. 2A). Muscle MRI scans of the lower limbs were 
performed in four patients (one LGMD2B and three MM pa-
tients). MRI scans revealed that the gastrocnemius, soleus, ad-
ductor magnus, hamstrings and vastus lateralis muscles had 
dominantly fatty atrophic changes and diffuse patchy edema 
(Fig. 2B).
Comparison between MM and LGMD2B types
We classified 30 symptomatic patients according to their initial 
patterns of muscle weakness. Fifteen patients had initial clinical 
presentation of calf weakness in one or both legs (MM group). 
Thirteen patients had proximal leg weakness (LGMD2B group), 
and two patients showed both proximal and distal weakness of 
the leg simultaneously (PD group). There was no difference be-
tween the LGMD2B and MM groups in the age of onset (LGM-
D2B group: 23.69 ± 8.99 yr; MM group: 22.00 ± 6.16 yr; P = 0.562) 
and the mean disease duration (LGMD2B group: 10.23 ± 6.02 
yr; MM group: 7.20 ± 7.74 yr; P = 0.264). There was a tendency 
for a higher proportion of women in the LGMD2B group (11/13 
patients, 85%) than in the MM group (7/16 patients, 47%; P =  
0.055). Table 3 shows the difference of clinical and laboratory 
characteristics between the LGMD2B and MM groups. The weak-
ness of proximal arm and leg is more frequently present in the 
LGMD2B group than the MM group. Anterior compartment mus-
cles of the lower leg were frequently affected in both LGMD2B 
and MM groups. In pathological findings and serum CK levels, 
there were no differences between LGMD2B and MM groups.
DISCUSSION
Our study reveals that clinical and pathological features of Korean 
dysferlinopathy patients vary greatly. Even though the majority 
experienced their first symptoms between the ages of 15 and 30, 
the patients had a broad range of age of onset from 12 to 36 yr. 
Although classical MM and LGMD2B phenotypes are most com-
mon, 31 patients evaluated in this study had a heterogeneous 
clinical spectrum from isolated hyperCKemia to proximodistal 
phenotype as shown in previous studies (7, 16-18). The factors 
responsible for distinct clinical features are yet unknown in our 
study. Muscle assessment and radiological studies demonstrat-
ed that the upper limb muscles were relatively preserved, but 
posterolateral compartments of the lower limb muscles were 
dominantly impaired. In the comparison between the MM and 
LGMD2B groups in our study, there were no differences of on-
set age, serum CK levels, and pathological findings. The dysfer-
linopathy patients had markedly elevated serum CK levels. In 
addition, the serum CK level correlated with the patient’s age, 
but did not correlate with disease duration in contrast with pre-
vious studies (7, 19). This is probably associated with a poor re-
lationship with disease progression and the serum CK or histo-
pathological changes of each patient (20). The pathological find-
ings of dysferlinopathy also revealed various features from nor-
mal findings to severe dystrophic changes in routine histopath-
ologic stains as were shown in previous studies (21). In our study, 
four patients had been misdiagnosed with an inflammatory my-
opathy similar to other reports (22-24). Dysferlinopathy is poten-
tially misdiagnosed as inflammatory myopathy due to several 
reasons. First, inflammatory cell infiltration is frequently observed 
in muscle specimens of dysferlinopathy as well as inflammato-
ry myopathy. Inflammatory cell infiltration may be associated 
with impaired secretion of cytokines and prolonged release of 
endogenous molecules such as heat shock proteins, high mo-
bility group box 1, and adenosine triphosphates due to compro-
mised membrane repair (25-27). Second, dyferlinopathy and 
inflammatory myopathy have common features such as very 
high serum CK levels and young adult onset. Third, many pa-
tients with dysferlinopathy had good muscle strength prior to the 
onset of symptoms (18), which can be suggestive of an acquired 
myopathy. Recent study revealed the analyzing inflammatory 
cells, MHC class I expressions and MAC deposits in a muscle 
specimen may contribute to differentiating dysferlinopathy from 
inflammatory myopathy (28). However, the best way for differ-
ential diagnosis between dysferlinopathy and inflammatory 
myopathy is to confirm the loss of dysferlin protein or gene.
 Dysferlinopathy usually has young adult onset and shows high 
serum CK levels. However, heterogeneity of clinical presenta-
tions and pathological findings on routine histopathological 
stains makes it difficult to diagnose dysferlinopathy. Currently 
the most important and easy method for differential diagnosis 
of dysferlinopathy is immunohistochemical staining. Even though 
western blotting can quantitatively measure the amount of pro-
tein present, it is time-consuming and not compulsory for all 
proteins on a routine basis. Western blotting can detect the pres-
ence of a protein, not the protein function (11). In addition, im-
munohistochemistry and western blotting both require assess-
ment by invasive muscle biopsy. Even if genetic testing is a less 
Table 3. Comparison of clinical and laboratory features for MM and LGMD2B groups
Findings
LGMD2B  
(n = 13)
MM  
(n = 15)
P value
Clinical finding
   Proximal arm weakness
   Distal arm weakness
   Proximal leg weakness
   Anterior distal leg weakness
   Posterior distal leg weakness
 
10 (77%)
  6 (46%)
  13 (100%)
10 (77%)
10 (77%)
 
  4 (27%)
  2 (13%)
  7 (47%)
  9 (60%)
  15 (100%)
 
0.008
0.096
0.002
0.435
0.087
Laboratory finding 
   Serum CK (fold)
 
40.92 ± 40.15
 
35.47 ± 22.19
 
0.658
Pathological finding
   Internal nuclei
   Necrotic and regenerative fiber
   Inflammatory cell infiltration
   Endomysial fibrosis
 
  8 (62%)
  13 (100%)
  9 (69%)
  7 (54%)
 
  6 (40%)
12 (80%)
10 (67%)
10 (67%)
 
0.256
0.226
1.000
0.488
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invasive and more accurate method, it is currently limited for 
diagnosing dysferlinopathy in clinical use due to the large size of 
dysferlin gene and the absence of a mutational hot spot (29, 30). 
 In conclusion, limitations in diagnosis by clinical and patho-
logical means currently make immunohistochemistry the most 
important method for patients suspected to have dysferlinopa-
thy. However, with advancing technology, genetic testing will 
be the most useful method for diagnosis of dysferlinopathy in 
the near future. 
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